Moderna Inc (NASDAQ:MRNA) price on current trading day, fall -0.37% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $27.25.
A look at the stock’s price movement, the level at last check in today’s session was $27.35, moving within a range at $26.54 and $27.35. The beta value (5-Year monthly) was 1.859. Turning to its 52-week performance, $148.84 and $23.15 were the 52-week high and 52-week low respectively. Overall, MRNA moved 13.45% over the past month.
Moderna Inc’s market cap currently stands at around $10.54 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Apr-30.
Analysts have a consensus estimate of 116.85M for the company’s revenue for the quarter, with a low and high estimate of 67.8M and 158M respectively. The average forecast suggests down to a -51.51% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.07B, representing a -35.95% decline on that reported in the last financial year.
17 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 12 recommend MRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRNA’s current price about 1.26% and 3.70% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.67, while 7-day volatility ratio is 1.90% and 3.73% in the 30-day chart. Further, Moderna Inc (MRNA) has a beta value of 1.86, and an average true range (ATR) of 1.46. Analysts have given the company’s stock an average 52-week price target of $47.5, forecast between a low of $45 and high of $50. Looking at the price targets, the low is -65.14% off recent price level in today’s trading while to achieve the yearly target high, it has to move -83.49%. Nonetheless, investors will most likely welcome a -74.31% jump to $47.5 which is the analysts’ median price.
If we refocus on Moderna Inc (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 11.79 over the past 10 days and 10.68 million over the past 3 months. The company’s latest data on shares outstanding shows there are 387.00 million shares.
The 11.44% of Moderna Inc’s shares are in the hands of company insiders while institutional holders own 72.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 65.86 million on 2025-05-30, giving us a short ratio of 4.73. The data shows that as of 2025-05-30 short interest in Moderna Inc (MRNA) stood at 2364.0 of shares outstanding, with shares short rising to 60.22 million registered in 2025-04-30. Current price change has pushed the stock -34.46% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.
